- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Prospective, Single centre
- Study aim: To describe remdesivir’s safety profile and patient outcomes in a subset of high-risk haematological patients treated with more than 10 days of remdesivir in the Omicron era
- Number of participants enrolled: 18
- Study enrolling from to
- Study includes follow-up for 1 month
Study Data
- Adults
- Elderly
- Fragile population
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
External Links
Other information
Funders:
- Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse
- Collège des Universitaires de Maladies Infectieuses et Tropicales
- Ministerio de Sanidad y Consumo
- Agencia de Gestión de Ayudas Universitarias y de Investigación (AGAUR) of Catalunya
- Instituto de Salud Carlos III
- European Union
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to